2024 ECTRIMS研究确定了 sNfL和 sGFAP 生物标志,预测MS残疾进展。 2024 ECTRIMS study identifies sNfL and sGFAP biomarkers predicting MS disability progression.

ECTRIMS 2024年提交的一份研究报告确定了可以预测多发硬化症中残疾恶化的生物标志。 A study presented at ECTRIMS 2024 identified biomarkers that can predict worsening disability in multiple sclerosis (MS). 高血清神经纤维素光链(sNfL)在疾病发端水平与45%的复发相关恶化风险增加(RAW)和43%的复发活动以外的复发风险增加(PIRA)相关联。 Elevated serum neurofilament light chain (sNfL) levels at disease onset were linked to a 45% increased risk of relapse-associated worsening (RAW) and a 43% risk of progression independent of relapse activity (PIRA). 此外,高血清质纤维酸蛋白 (sGFAP) 水平与低sNfL患者的PIRA相关. Additionally, high serum glial fibrillary acidic protein (sGFAP) levels correlated with PIRA in patients with low sNfL. 这些发现可能有助于为MS患者提供个性化治疗策略. These findings may facilitate personalized treatment strategies for MS patients.